Feature | September 28, 2012

Analyst Insight: Abbott’s Absorb is the New Face of the Stent Industry

Abbott Bioabsorbable Stent  Absorb

September 28, 2012 — The world’s first drug-eluting bioabsorbable vascular scaffold has been launched and will revolutionize the stent industry. On Sept. 25, 2012, Abbott announced the launch of its drug-eluting bioabsorbable stent, Absorb, in Europe, the Middle East and parts of Asia Pacific and Latin America. Absorb, which received CE mark certification in 2011, is used to treat coronary artery disease. Bioabsorbable stents, such as Absorb, will broaden treatment and diagnostic options, reduce the need for long-term anti-platelet therapy and reduce the risk of in-stent restenosis and thrombosis.

Coronary artery disease is a progressive condition, characterized by stenosis and occlusion of the coronary arteries. The prevalence of coronary artery disease is increasing worldwide and can be attributed to the growing aging population and risk factors such as diabetes and hypertension. There is a continuous need for better treatment options and expansion of access to therapies among underserved populations.

Absorb is designed to open blocked coronary arteries and restore blood flow to the heart.  The stent consists of a biodegradable polymer backbone composed of PLLA (poly-L-lactic acid) with a PDLLA (poly-D,L-lactide) bioabsorbable polymer coating that controls the release of the anti-proliferative drug, everolimus. It provides transient support to the vessel wall to prevent recoil and is absorbed by the body over a period of two years. As the stent is absorbed overtime, it relieves patients of a permanent metallic fixture and has the potential to allow the healed vessel to function normally and respond to stimuli. Clinical outcomes have indicated that Absorb performs similar to best-in-class drug-eluting stents across measures such as major adverse cardiac events and target lesion revascularization, with the added benefit of disappearing over time. Absorb is currently in trials in the United States and does not have regulatory approval.

Since their launch in 2003, drug-eluting stents have been adopted worldwide. Several clinical trials have demonstrated that drug-eluting stents can significantly improve clinical outcomes compared to bare metal stents and balloon angioplasty. However, there are several complications with drug-eluting stents such as late-stent thrombosis, need for long-term anti-platelet therapy and incompatibility with imaging modalities. These unmet needs have been addressed with the development of bioabsorbable stents, such as Absorb. The potential long-term benefits of a degradable stent system are significant, making it attractive to physicians and patients. Future interventions can be performed effectively without any obstruction by a permanent implant.

Prior to Absorb making its debut, the Igaki-Tamai (Remedy), developed by Kyoto Medical Planning, was the first bioabsorbable stent commercially available in Europe and Turkey. The Igaki-Tamai stent, a non-drug eluting bioabsorbable stent composed of PLLA polymer, was originally developed to treat coronary artery disease. However, due to unfavorable clinical trial outcomes, the focus was shifted to peripheral use. Recently, long-term clinical outcomes demonstrating the safety and efficacy of the Igaki-Tamai stent for coronary artery disease were published, prompting Kyoto Medical Planning to review its use in coronary applications. The company is expected to apply for CE mark and U.S. Food and Drug Administration approval in the next two years. Another company, Biotronik, is also developing drug-eluting bioabsorbable metal stents (DREAMS) that provide greater radial strength to the vessel than polymer-based bioabsorbable stents and are hypo-thrombogenic.

With the commercial international launch of Absorb, the competitive landscape of the stent market has changed. Adoption of Absorb will vary across regions, depending on the economic status, patient or physician preference and availability of medical reimbursement and marketing in the country. As more long-term clinical data becomes available over the next few years, GlobalData believes the use of bioabsorbable stents will increase compared to drug-eluting stents. Stent manufacturers such as Boston Scientific and Medtronic should expect to see a loss of market share. Bioabsorbable stents are the new wave of stents and are here to stay.

For more information: www.globaldata.com/ExpertsInsightDetails.aspx?PRID=396&companyID=jpr

Related Content

ACC late breakers
News | ACC| February 09, 2016
February 9, 2016 — The late-breaking clinical trial presentations have been announced for the 2016 American College o
transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting| February 02, 2016
Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES,...
TOBA-BTK study, six-month results, LINC 2016, Tack Endovascular System
News | Peripheral Arterial Disease (PAD)| January 29, 2016
Intact Vascular Inc. announced that positive six-month results from its Tack Optimized Balloon Angioplasty – Below-the-...
Toshiba, CT-angiography, hybrid OR

Toshiba recently introduced a new line of combined CT and angiography systems, allowing true CT imaging on demand in the interventional lab.

Feature | Angiography| January 27, 2016 | Dave Fornell
All of the major vendors in the United States introduced new systems and technologies in the past few years to reduce...
Technology | Ultrasound Intra-cardiac Echo (ICE)| January 26, 2016
Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received U.S. Food and Drug Administration (FDA) 510(k)...
medical device excise tax, two-year suspension, U.S. market, GlobalData analyst
News | Business| January 25, 2016
The suspension of the medical device excise tax will have positive consequences for the U.S. medical device market over...
Abbott, Absorb, BVS, FDA review, FDA panel

The Abbott Absorb BVS.

News | Cath Lab| January 20, 2016 | Dave Fornell
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel is set to review data and offer...
Overlay Init